ERBB2 and breast carcinoma: The present study involved a multiomics analysis of patients with HR– and HER2-low breast cancer (hereafter, HER2-low TNBC) from Fudan University Shanghai Cancer Center (FUSCC) and data from The Cancer Genome Atlas (TCGA) to exhibit a broad molecular spectrum of HER2-low TNBC, reveal molecular subgroups, and provide potential clinical relevance.